Diasorin rises on new product clearance from U.S. FDA

DiaSorin SpA

05/06/2024 10:20

** Shares in Italy's DiaSorin  DIAS.MI  rise as much as 1.6%
after the medical diagnostic group obtained clearance for its
new product Liaison Plex Yeast Blood Culture Assay from the U.S.
Food and Drug Administration.    
    ** The product is the second multiplexing molecular
diagnostic panel on the Liaison PLEX platform and allows the
identification of 16 pathogens commonly associated with the 
presence of fungi in the blood.
    ** Equita says it is positive news, highlighting that the 
"Liaison PLEX platform is the main growth driver of DiaSorin's
molecular division," which is expected to have a 15% compound
annual growth rate in 2024-2027.
    ** Banca Akros says the news confirms the industrial plan
announced in December 2023 is on track.
    ** At Tuesday's close, shares were up 6.7%​ YTD

    
    
    
    
    
    
  

 (Reporting by Alberto Chiumento, editing by Gavin Jones)
 ((Alberto.Chiumento@thomsonreuters.com;))